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 A high-dose (24g/24h) piperacillin CI may not always ensure adequate exposure 32 
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Abstract 36 
Dosing recommendations for continuous infusion of piperacillin, a broad-spectrum beta-37 
lactam antibiotic, are mainly guided by outputs from population pharmacokinetic models 38 
constructed with intermittent infusion data. However, the probability of target attainment in 39 
patients receiving piperacillin by continuous infusion may be overestimated when drug 40 
clearance estimates from population pharmacokinetic models based on intermittent infusion 41 
data are used, especially when higher doses (e.g. 16g/24h or more) are simulated. Therefore, 42 
the purpose of this study was to describe the population pharmacokinetics of piperacillin 43 
when infused continuously in critically ill patients. For this analysis, 270 plasma samples 44 
from 110 critically ill patients receiving piperacillin were available for population 45 
pharmacokinetic model building. A one-compartment model with linear clearance best 46 
described the concentration-time data. The mean ± SD parameter estimates were 8.38 ± 9.91 47 
L/h for drug clearance and 25.54 ± 3.65 L for volume of distribution. Creatinine clearance 48 
improved the model fit and was supported for inclusion as a covariate. In critically ill patients 49 
with a renal clearance higher than 90 mL/min/1.73m
2
, a high-dose continuous infusion of 50 
24g/24h is insufficient to achieve adequate exposure (pharmacokinetic/pharmacodynamic 51 
target of 100% fT>4 x MIC) against susceptible P. aerginosa isolates (MIC ≤ 16mg/L). These 52 
findings suggest that merely increasing the dose of piperacillin, even with continuous 53 
infusion, may not always result in adequate piperacillin exposure. This should be confirmed 54 
by evaluating piperacillin target attainment rates in critically ill patients exhibiting high renal 55 
clearance. 56 
Keywords 57 
Beta-lactam antibiotic, pharmacokinetics, piperacillin, continuous infusion, critically ill 58 
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Abbreviations 60 
ICU: intensive care unit 61 
MIC: minimal inhibitory concentration 62 
% fT>MIC: proportion of the dosing interval that unbound concentrations remain above the 63 
MIC 64 
II: intermittent infusion 65 
CI: continuous infusion 66 
PK: pharmacokinetics 67 
PD: pharmacodynamics 68 
PTA: probability of target attainment 69 
ECMO: extracorporeal membrane oxygenation 70 
RRT: renal replacement therapy 71 
CLCR: creatinine clearance 72 
SOFA: sequential organ failure assessment  73 
APACHE II: acute physiology and chronic health evaluation 74 
TPN: total parenteral nutrition 75 
UPLC – MS/MS: ultra-high performance liquid chromatography coupled to tandem mass 76 
spectrometry 77 
LLOQ: lower limit of quantification 78 
NPAG: non-parametric adaptive grid 79 
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Css: steady state concentration 80 
AIC: Akaike information criterion  81 
EUCAST: European committee on antimicrobial susceptibility testing 82 
CLCR CG: renal clearance as estimated by the Cockroft-Gault equation 83 
FTA: fractional target attainment 84 
CLCR 8h: renal clearance as estimated by 8-hourly urinary creatinine measurements 85 
CLCR MDRD: renal clearance as estimated by the Modification of Diet in Renal Disease 86 
equation 87 
TVCL: typical value of drug clearance 88 
CL: drug clearance 89 
Vd: volume of distribution 90 
ARC: augmented renal clearance 91 
SIRS: systemic inflammatory response syndrome 92 
TDM: therapeutic drug monitoring  93 
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1. Introduction 94 
The mortality, morbidity and the cost of sepsis in the Intensive Care Unit (ICU) 95 
remains an important and persisting health issue worldwide[1,2]. With a mortality rate of 96 
approximately 30%, sepsis is one of the leading causes of death in the ICU [3]. The 97 
cornerstone in the treatment of sepsis is antibiotic therapy, with a focus on the timely 98 
administration and appropriateness of the antimicrobial spectrum of the drug prescribed [4]. 99 
Optimizing antibiotic dosing is considered an opportunity to improve clinical cure rates for 100 
infected patients and to aid in the suppression of resistance [5]. Roberts, et al. [6] were able to 101 
demonstrate that administration of beta-lactam antibiotics by continuous infusion in critically 102 
ill patients with severe sepsis was associated with decreased hospital mortality in a recent 103 
meta-analysis of individual patient data from randomized clinical trials. 104 
Piperacillin, typically co-administered with the beta-lactamase inhibitor tazobactam, 105 
is a broad-spectrum beta-lactam antibiotic often prescribed to treat infections in critically ill 106 
patients [7]. Like other beta-lactam antibiotics, piperacillin exerts time-dependent killing, 107 
meaning that the time (T) for which the free (f) or unbound fraction of the drug exceeds the 108 
minimal inhibitory concentration (MIC) (% fT>MIC) is related to its antimicrobial activity [8]. 109 
Standard practice is to infuse piperacillin as intermittent 30-min infusion (II).  However, 110 
continuous infusion (CI), i.e. a continuous infusion rate during the entire dosing interval, has 111 
been adopted as mode of infusion in several institutions [9]. A growing level of evidence is 112 
emerging showing that CI is more likely than II to ensure beta-lactam antibiotic 113 
concentrations above the MIC throughout the dosing interval [10].  114 
Critically ill patients may manifest profound pharmacokinetic (PK) variability when 115 
compared to healthy volunteers or non-critically ill patients [11]. Therefore, dosing regimens 116 
based on dose-finding studies in healthy volunteers or non-critically ill patients may not 117 
apply in critically ill patients [12]. In recent years, many PK studies have been performed 118 
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including data from critically ill patients. These specific population PK models have been 119 
used to identify dosing regimens with a high probability of achieving adequate antibiotic 120 
concentrations in ICU patients. However, the pharmacodynamic (PD) evaluation of CI 121 
piperacillin mainly relies on PK parameters estimated from studies where piperacillin was 122 
administered intermittently [13].  123 
The objective of this study was to evaluate the population pharmacokinetics and 124 
probability of target attainment (PTA) of piperacillin when infused continuously in critically 125 
ill patients. We evaluated various doses for varying renal clearances over a range of MICs to 126 
determine optimal CI dosing regimens in this population. 127 
2. Materials and methods 128 
2.1 Setting 129 
This observational study was a single centre study at Ghent University Hospital ICU, a 130 
tertiary ICU. Ethical approval was obtained from the Ghent University Hospital Ethics 131 
Committee (registration number 2016/0264). The need for written consent was waived by the 132 
Ethics Committee and blood samples were collected under opt-out sampling.  133 
2.2 Inclusion and exclusion criteria 134 
Patients were eligible for inclusion if they were admitted to the surgical ICU and received 135 
piperacillin in CI. Patients receiving extracorporeal membrane oxygenation (ECMO) or renal 136 
replacement therapy (RRT) during piperacillin/tazobactam therapy and patients younger than 137 
18 years were excluded. 138 
2.3 Study protocol 139 
Eligible patients received piperacillin/tazobactam in CI, standard dosing was 16/2g /24h. This 140 
dose was adapted, either decreased or increased, based on the patient’s kidney function (<15 141 
ml/min: 8/1g /24h, 15-29 ml/min: 12/1.5g /24h, 30-129 ml/min: 16/2g /24h, 129-199 ml/min: 142 
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20/2.5g /24h, >200 ml/min: 24/3g /24h). All patients received a loading dose (4/0.5g 143 
piperacillin/tazobactam) immediately prior to initiating the CI. For every patient, creatinine 144 
clearance (CLCR) was determined by measuring urinary creatinine concentrations in an 8-145 
hour urinary collection using an indwelling urinary catheter. Additional data, such as 146 
additional biochemistry, demographic data, the modified Sequential Organ Failure 147 
Assessment (SOFA) score, the Acute Physiology and Chronic Health Evaluation (APACHE 148 
II) score on admission, the 24h fluid balance and in-hospital mortality was prospectively 149 
recorded.  150 
2.4 Sampling and storage 151 
For this study, a residual sample of the 3mL blood gas tubes (lithium heparin blood gas tubes 152 
by Siemens, Tarrytown, USA) was sent to the core laboratory of the Dept. of Laboratory 153 
Medicine at the Ghent University Hospital where they are first stored in a 4°C refrigerator 154 
until they were collected by the toxicology laboratory technicians and labelled and transferred 155 
to a 1.5 mL Eppendorf tube. Storage is the 4°C refrigerator was no longer than 24 hours. 156 
After transferring to an Eppendorft tube, plasma samples were centrifuged at 16162xg for 8 157 
minutes (Beckman Coulter, Brea, California). Immediately afterwards, the plasma samples 158 
were stored at -80°C until analysis. All samples were analysed within 3 months. The plasma 159 
concentration of piperacillin was determined by ultra-high performance liquid 160 
chromatography coupled to tandem mass spectrometry (UPLC – MS/MS). The lower limit of 161 
quantification (LLOQ) for piperacillin was 1.5 mg/L [14]. 162 
2.5 Population PK modelling and simulation 163 
Concentration-time data were analysed using Pmetrics (version 1.5.0), an R-based software 164 
program for non-parametric and parametric pharmacokinetic-pharmacodynamic population 165 
and individual modelling and simulation. We used the non-parametric adaptive grid (NPAG) 166 
algorithm to build a population PK model for piperacillin in CI [15]. A digital Fortran 167 
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compiler was used (Gfortran version 6.1) and the runs were executed using RStudio (version 168 
1.0.136). Steady state concentrations (Css), defined as samples drawn no earlier than 6 hours 169 
after initiation of antibiotic therapy, were collected from patients admitted to the surgical ICU 170 
between March 1th 2016 and November 30
th
 2016. First, data was fitted to a one-, two and 171 
three-compartment model using subroutines from the Pmetrics library.  Modeling 172 
concentration-time data with both linear and parallel first-order Michaelis-Menten drug 173 
clearance was attempted. Next, the statistical error model with the best fit was selected and a 174 
covariate model was developed. Finally, the model fit was evaluated and Monte Carlo 175 
simulations were run (n = 1000).  176 
2.6 Pharmacokinetic model diagnostics 177 
The PK model was assessed by visual evaluation of the goodness of fit of the observed-178 
predicted plots and the coefficient of determination of the linear regression of the observed-179 
predicted values (r
2 
close to 1, intercept close to 0) from each run. The predictive 180 
performance was assessed on mean prediction error (bias) and the mean bias-adjusted 181 
squared prediction error (imprecision) of the population and individual posterior predictions. 182 
In addition, log likelihood and the Akaike information criterion (AIC) was considered and a 183 
visual predictive check was performed by overlaying the 95% confidence interval of the 184 
simulated profiles for 0.05, 0.5 and 0.95 quantiles with the corresponding quantiles of 185 
observed data.  186 
2.7 Pharmacodynamic analysis and dosing simulations 187 
Monte Carlo simulations were performed to determine the PTA for a PK/PD target of 100% 188 
fT>4 x MIC for scenario’s with MIC 1, 4, 8 and 16 mg/L. An MIC of 16 mg/L is the clinical 189 
breakpoint for Pseudomonas aeruginosa published by the European Committee on 190 
Antimicrobial Susceptibility Testing (EUCAST) [16]. This breakpoint, the upper limit of 191 
piperacillin susceptibility, represents a worst-case scenario for empirical dosing. A free 192 
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fraction of 70% of the total concentration was used, assuming a level of protein binding of 193 
30% for piperacillin [17]. A loading dose of 4g piperacillin, immediately followed by a 194 
continuous infusion of 8g, 12g, 16g, 20g and 24g CI was simulated for patients with a CLCR 195 
estimated by Cockroft-Gault (CLCR CG) equation of 30, 60, 90, 120, 150, 180, 210, 240, 270 196 
and 300 mL/min/1.73m
2
. 197 
2.8 Fractional Target Attainment 198 
To determine the likely success of treatment, the fractional target attainment (FTA) was 199 
calculated comparing the PTA of a standard piperacillin regimen (16g) against the wild-type 200 
MIC distribution of P. aeruginosa. To calculate the FTA, the PTA at each MIC was 201 
multiplied by the percentage of isolates found at that MIC. Information on the wild-type 202 
distribution of P. aeruginosa was obtained from the EUCAST database [16] . The FTA was 203 
calculated for a PK/PD target of 100% fT>4 x MIC for susceptible P. aeruginosa isolates (MIC 204 
≤ 16 mg/L) for both the standard CI regimen (16g/24h) and the high-dose CI regimen 205 
(24g/24h). Dosing was a priori considered successful if the FTA was at least 95%. 206 
2.9 Statistical analysis 207 
All statistical analyses were performed using SPSS version 24 software (IBM SPSS, Chicago, 208 
IL, USA). Continuous data are presented as the mean (standard deviation) or median 209 
(interquartile range). Categorical data are presented as counts (%).  210 
3. Results 211 
3.1 Demographic data 212 
In total, 110 patients were included and a total of 271 samples were available. One 213 
concentration was excluded from analysis because of an inaccuracy in the dilution of 214 
deuterated internal standard. 270 concentrations were included for population PK model 215 
construction. 244 samples were available for urinary creatinine analysis. Of all 244 samples, 216 
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77 (31.5%) samples had an 8-hour creatinine clearance equal to or higher than 130 217 
mL/min/1.73m
2
. Table 1 provides additional demographic, anthropometric, illness severity, 218 
biochemical, admission and outcome data. 219 
TABLE 1 220 
3.2 Plasma concentration data 221 
Median unbound piperacillin concentration was 58.1 mg/L (IQR 41.2 - 84 mg/L), assuming a 222 
30% level of protein binding for piperacillin.  223 
3.3 Pharmacokinetic model building  224 
A one-compartmental model with linear elimination was found to best describe our data. 225 
Table 2 summarizes the log-likelihood values, coefficients of determination (r
2
 values), and 226 
predictive performance of linear and parallel first-order non-linear models. Evaluation of the 227 
log likelihood values against a
 χ2  distribution and comparison of the coefficient of 228 
determination, bias, imprecision and AIC indicated that the parallel first-order Michaelis-229 
Menten model was not superior compared to a linear model.  230 
TABLE 2 231 
Including CLCR CG normalized to 100 mL/min/1.73m
2
 as a model covariate improved the PK 232 
model fit (table 3). This was described as follows in the final model: TVCL = CL*(CLCR 233 
CG/100). TVCL refers to the typical value of piperacillin clearance and CL refers to the 234 
population parameter estimate of piperacillin clearance. 235 
TABLE 3 236 
Other covariates such as weight, SOFA score, APACHE II score, albumin and bilirubin were 237 
tested as well but did not improve our model fit (data not shown). As our data file did not 238 
contain concentrations measured during the administration of the loading dose, the volume of 239 
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distribution (Vd) could not be accurately estimated and was fixed to a range of 10 – 45 L. The 240 
means ± standard deviations for population parameters of piperacillin in the patients analysed 241 
were 8.38 ± 9.91 L/h for CL and 25.54 ± 3.65 L for Vd. The interindividual variability was 242 
43.61% for CL and 38.79% for Vd. Figure 1 represents the population predicted versus 243 
observed and individual predicted versus observed diagnostic plots. The visual predictive 244 
check plot is depicted in figure 2. Based on the diagnostic plots, the gamma error model, a 245 
multiplier of assay variance, was selected for modelling intra-individual variability.  246 
FIGURE 1 247 
FIGURE 2 248 
3.4 Probability of target attainment 249 
The PTA for different dosing regimens of piperacillin in critically ill patients with varying 250 
renal clearance for different MIC scenarios and the PK/PD target of 100% fT>4 x MIC is 251 
depicted in figure 3.  252 
FIGURE 3 253 
3.5 Fractional Target Attainment 254 
For susceptible P. aeruginosa isolates (MIC ≤ 16 mg/L), the FTA for a standard dose CI 255 
regimen of piperacillin (4g loading dose, followed by a 16g CI) and a high-dose CI regimen 256 
of piperacillin (4g loading dose, followed by a 24g CI) for the PK/PD target of 100% fT>4 x 257 
MIC is presented in table 4. The wild type MIC distribution for P. aeruginosa as provided by 258 
EUCAST has been used [16]. 259 
TABLE 4 260 
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4 Discussion 261 
We evaluated the impact of increasing CLCR and decreasing bacterial susceptibility on 262 
the PTA when piperacillin was infused continuously in critically ill patients. A high-dose CI 263 
regimen of a 4g loading dose followed by a CI of 24g/24h is insufficient to achieve adequate 264 
exposure (PK/PD target of 100% fT>4 x MIC) against susceptible P. aeruginosa isolates (MIC ≤ 265 
16mg/L) in critically ill patients with a renal clearance higher than 90mL/min/1.73m
2
. For 266 
patients specifically infected with bacteria with an MIC of 16 mg/L, the upper limit of the 267 
piperacillin susceptible range, conventional dosing (16g/24h) and a high-dose infusion 268 
(24g/24h) cease to provide adequate exposure as soon as renal clearance exceeds 269 
50mL/min/1.73m
2 
and 65mL/min/1.73m
2 
respectively, highlighting the important impact of 270 
CLCR and PK variability on the PTA in critically ill patients. 271 
Augmented renal clearance (ARC) is increasingly recognized as an important risk 272 
factor for low beta-lactam antibiotic trough or steady-state concentrations. ARC has been 273 
attributed to the systemic inflammatory response syndrome (SIRS) commonly seen in 274 
critically ill patients. SIRS may increase cardiac output and decrease vascular resistance 275 
thereby increasing renal blood flow and the glomerular filtration rate. Increased tubular 276 
secretion of anions during sepsis is also suggested as a mechanism leading to increased renal 277 
clearance of anionic antibiotics such as piperacillin [18]. ARC strongly predicts low beta-278 
lactam trough concentrations but the relation between ARC and clinical outcome is unclear 279 
[19]. In a sub-study of the BLING-II (Beta-Lactam Infusion Group) study, alive ICU-days at 280 
day 28 after randomisation were compared between patients with and without ARC. ARC 281 
was not associated with adverse patient outcomes [20].  282 
Our simulations indicate that even a high-dose CI (24g/24h) would not be sufficient to 283 
ensure target piperacillin exposures in a substantial number of ICU patients. While we realise 284 
that the FTA in our study was calculated for a relatively ‘high’ PK/PD target (100% fT>4 x 285 
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MIC), experts are increasingly arguing in favour of this PK/PD target [21]. Nevertheless, it is 286 
important to recognise that PK/PD targets found in preclinical studies for beta-lactam 287 
antibiotics are mainly based on plasma rather than tissue PK [22]. In critically ill patients 288 
however, piperacillin tissue penetration may be highly variable, which complicates 289 
extrapolations from preclinical studies where plasma PK was simulated to determine the 290 
optimal PK/PD target [11,23].  291 
There is a need to document target attainment rates in critically ill patients and 292 
validate our simulations, especially in the subset of ICU patients with high renal function and 293 
infected with less susceptible pathogens. Recently, Aardema, et al. [24] evaluated PK/PD 294 
target attainment for 100% fT>4 x MIC and MIC of 16 mg/L in critically ill patients receiving a 295 
loading dose of 4g/0.5g followed by a CI of 12g/1.5g piperacillin/tazobactam over 24 hours. 296 
In their analysis, only 5 out of the 18 patients achieved 100% fT>4 x MIC within one hour after 297 
initiation of therapy and maintained concentrations at this level or higher for the entire 298 
treatment duration. The median CLCR in this population was 62.5 mL/min/1.73m
2 
(compared 299 
with a measured CLCR of 110 mL/min in this study). According to our simulations, with a 300 
loading dose of 4g followed by a 12g CI for a worst-case scenario (MIC = 16 mg/L) and a 301 
renal clearance of 62.5 mL/min/1.73m
2
, the PTA (100% fT>4 x MIC) would be 48%, which is in 302 
agreement with the findings of Aardema, et al. [24]. 303 
Our results seem to compromise the utility of piperacillin/tazobactam monotherapy in 304 
critically ill patients exhibiting a high CLCR and infected with high-MIC bacteria. To 305 
circumvent this issue, several strategies are worth considering. First, although combination 306 
therapy of piperacillin/tazobactam with, for example, amikacin has not proven to be 307 
associated with improved outcomes, in vitro experiments suggest that piperacillin 308 
concentrations when used in combination therapy may not need to be as high compared to 309 
concentrations when piperacillin is used as monotherapy [25,26]. Second, the lack of 310 
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individual exposure-response data may cloud the relationship between piperacillin exposure 311 
and clinical outcome. Therapeutic drug monitoring (TDM) may help optimise dosing in 312 
individual critically ill patients because of the marked and well-documented pharmacokinetic 313 
variability in this subgroup of patients [11]. Several institutions are using TDM to monitor 314 
beta-lactam drug concentrations[27].  However, the clinical use of TDM remains limited 315 
because the most common assay method for beta-lactam TDM is an expensive and labour-316 
intensive chromatographic method, leading to a significant delay between sample time and 317 
result [27]. Currently, bedside tools for beta-lactam antibiotics such as microfluidic lab-on-a-318 
chip systems are being developed with a significantly faster sample-to-result time, but they 319 
are not yet ready for routine application [28]. In patients exhibiting high renal clearance and 320 
in whom high-MIC bacteria are isolated, determining the MIC and performing TDM when 321 
initiating piperacillin therapy may be used to guide the physician in dose-adaptations.  322 
Third, when adequate exposure with piperacillin cannot be achieved, using an 323 
antibiotic with higher susceptibility may yet ensure adequate antibiotic therapy. 324 
Creatinine clearance is often identified as a covariate for total drug clearance of 325 
renally cleared drugs such as piperacillin [29]. In this PK model, the glomerular filtration rate 326 
estimated by the CG equation provided a better overall model fit compared to the glomerular 327 
filtration rate estimated by creatinine measurements in an 8-hourly urinary collection. 328 
Nevertheless, in critically ill patients, creatinine-based equations such as the CG formula to 329 
estimate glomerular filtration typically perform worse compared to urinary creatinine 330 
clearance measurements, although the measured value is assumed to be the best available 331 
data in those comparisons [30]. A possible explanation could be that estimating glomerular 332 
filtration rate to predict total drug clearance of piperacillin, either with urinary creatinine 333 
measurements or with the CG formula, will always only be an approximation of total drug 334 
clearance as non-renal clearance processes are also involved [31]. Indeed, the frequency with 335 
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which either of these GFR estimates is identified as the preferred statistical covariate of 336 
antibiotics clearance in critically ill patients is relatively similar.  337 
Piperacillin PK parameters may be different between II and CI modalities, especially 338 
when daily doses of 16g or higher are used. It is therefore relevant to construct a piperacillin 339 
PK model based on CI data. Conventionally, pharmacokinetic parameters obtained from II 340 
beta-lactam PK studies are used to predict a CI profile in simulation studies [13]. However, 341 
Vinks, et al. [32] have documented a significant higher piperacillin drug CL when 342 
piperacillin was administered in CI compared with II in their crossover study in cystic 343 
fibrosis patients. This difference was attributed to saturable renal elimination at clinically 344 
used doses. Piperacillin is renally cleared through glomerular filtration and tubular secretion 345 
(organic anion transporting polypeptide 1) [33,34]. Tubular secretion is a non-linear and thus 346 
saturable process while glomerular filtration is a linear process. Thus, estimating piperacillin 347 
drug CL with a parallel first-order and Michaelis-Menten clearance model is physiologically 348 
plausible [34].  In a piperacillin extended infusion PK study, Felton, et al. [34] estimated that 349 
just under half of the administered dose is cleared by the saturable Michaelis-Menten 350 
clearance. This finding is particularly relevant when higher daily doses are used (e.g. 16g) 351 
and when piperacillin is administered in CI versus II. Indeed, higher concentrations, e.g. with 352 
II or with higher daily doses, are more likely to saturate the tubular excretion process while 353 
this may not happen with CI or lower daily doses (e.g. 12g).  Li, et al. [35] however, did not 354 
confirm this finding of altered drug clearance with CI compared to II. In their analysis in 355 
patients with complicated intra-abdominal infections, CL for II was not statistically different 356 
from CL in CI (13.72 L/h versus 15.96 L/h). It is postulated nonetheless that the lack of a 357 
significant difference could be related to the use of 12g piperacillin instead of 16g piperacillin 358 
[13,32,34]. Others have suggested that differences in piperacillin clearance in the study by 359 
Vinks, et al. [32] could be attributed to a higher affinity of anion-selective pumps in the renal 360 
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tubules of cystic fibrosis patients [36]. Udy, et al. [37] however, demonstrated that renal 361 
tubular anion secretion was also enhanced in critically ill patients.  362 
An important limitation of our study is the lack of antibiotic concentrations during the 363 
administration of the loading dose. Indeed, because concentrations measured during the 364 
administration of the loading dose were not available, the Vd could not be accurately 365 
estimated and was therefore fixed to 10-45L. We also recognize that higher doses of 366 
piperacillin may potentially be neurotoxic. Quinton, et al. [38] recently identified a 367 
concentration threshold of 157.2 mg/L (Css) predicting neurotoxicity when piperacillin was 368 
infused continuously in critically ill patients. Colleagues Imani, et al. [39] document a much 369 
higher threshold concentration of 361.4 mg/L (Cmin), for which there is a 50% risk of 370 
developing a neurotoxicity event. In our simulations, we simulated for a PK/PD target of 371 
100% fT>4 x MIC. As such, in a worst-case scenario (MIC 16 mg/L), free concentrations 372 
necessary to achieve the PK/PD target are 64 mg/L, which is lower than the current threshold 373 
for neurotoxicity.  374 
Also, the unbound concentration of piperacillin was calculated and not measured in 375 
our study. To calculate unbound piperacillin concentrations, protein binding was fixed to 376 
30%, in accordance with previous findings [17], which is likely acceptable for piperacillin as  377 
Wong, et al. [40] could not demonstrate an association between altered protein binding and 378 
varying albumin concentrations for piperacillin. 379 
In conclusion, in an ICU-population, increasing renal clearance and decreasing 380 
pathogen susceptibility is strongly correlated with decreasing rates of target attainment. As 381 
even a high-dose CI regimen of piperacillin (24g/24h) may not ensure target exposure if renal 382 
clearance is high, increasing the dose of piperacillin will not always achieve target 383 
piperacillin exposures. These findings emphasise the need to (i) further explore alternative 384 
strategies to achieve optimal antibiotic exposure of renally cleared antimicrobials when 385 
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administered to critically ill patients with high renal clearance, (ii) incorporate tissue PK of 386 
critically ill patients in preclinical experiments evaluating the optimal PK/PD target, (iii) 387 
consider combination therapy or a different antibiotic and (iv) pursue individualised beta-388 
lactam antibiotic therapy, preferably via TDM and determination of the MIC whenever 389 
possible, especially in patients exhibiting high renal clearance. 390 
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Figure capitations and legends 539 
Capitation figure 1. Diagnostic scatter plots for piperacillin final PK model 540 
Legend figure 1. Diagnostic scatter plots for piperacillin final PK model. The population 541 
predicted versus observed concentration (left) and the individual predicted versus observed 542 
concentration (right) diagnostic plots. The line of unity is included. 543 
 544 
Capitation figure 2. Visual predictive check plot for piperacillin final model 545 
Legend figure 2. Visual predictive check plot of piperacillin plasma concentrations versus 546 
time for the final covariate model. Gray shadings represent predicted intervals of simulated 547 
data. 548 
 549 
Capitation figure 3. Probability of target attainment with varying CLCR. 550 
Legend figure 3. PTA for a PK/PD target of 100% fT>4 x MIC for piperacillin loading dose of 551 
4g followed by a continuous infusion of 8g (filled circles), 12 g (filled squares), 16 g (filled 552 
triangles, top up), 20 g (filled triangles, top down) and 24 g (filled 45° rotated square). The 553 
figures simulate various doses for the scenario of a MIC = 1 (fig 3A, upper left), followed by 554 
MIC = 4 (fig 3B, upper right), MIC = 8 (fig 3C, lower left) and MIC = 16 (fig 3D, lower 555 
right). The red dotted line refers to 90% PTA, the conventional cut-off.  556 
  557 
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Capitation table 1.  demographic, anthropometric, illness severity, biochemical, admission 558 
and outcome data 559 
Variable  N = 110 
Age, yr  60.0 (14.4) 
Male sex, n (%)  75.0 (68.2%) 
Weight, kg  78.3 (16.2) 
APACHE II score
a 
 19.8 (7) 
Modified SOFA
b
 score, median (IQR
c
)  6 (4-10) 
24-hour balance, ml  -602 (1625) 
Plasma creatinine, μmol/L  81.4 (60.7) 
Measured creatinine clearance (8 hour), mL/min/1.73m
2 
 107 (66.5) 
Estimated creatinine clearance Cockcroft-and-Gault, 
mL/min/1.73m
2 
 123 (67.6) 
ICU length of stay, days, median (IQR
c
)  10.5  (4-22) 
Admission category/system, n (%)   
 Medical 61 (55%) 
 Surgical 36 (33%) 
 Trauma 13 (12%) 
ICU mortality, n (%)  10 (9%) 
Hospital mortality, n (%)  20 (18%) 
Legend table 1. 
a
APACHE, Acute Physiology and Chronic Health Evaluation; 
b
SOFA, 560 
Sequential Organ Failure Assessment; 
c
IQR, Interquartile Range; 
d
MDRD, Modification of 561 
Diet in Renal Disease. Data presented are mean (SD) unless otherwise stated.562 
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Capitation table 2. Predictive performance of piperacillin population models 563 
  Linear regression of observed-predicted for each 
patient 
  
Model Log 
likelihood 
Intercept
 
Slope R
2
  Bias Imprecision AIC χ2 compared 
with linear 
model 
Linear -2535 0.48 1.06 0.85 -0.15 0.74 2541 NA 
Parallel first-
order/MM 
-2535 0.39 1.06 0.85 -0.15 0.73 2545 0.53 
Legend table 2. Predictive performance of linear and parallel first-order Michaelis Menten 564 
model. R
2
 is the coefficient of determination for the best-fit linear regression for the 565 
predicted-observed plot after the maximal a posteriori probability Bayesian step. AIC is the 566 
Akaike information criterion. NA, not applicable, χ2 is Chi-square statistic, MM is Michaelis-567 
Menten 568 
 569 
 570 
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Capitation table 3. Predictive performance of piperacillin population models 571 
  Linear regression of observed-predicted for each patient  
Model Log 
likelihood 
Intercept
 
Slope R
2
  Bias Imprecision AIC 
No covariate -5248 -8.03 1.20 0.70 -0.19 0.797 2630 
CLCR 8h -5194 22.40 0.81 0.71 -0.076 0.82 2604 
CLCR MDRD -5108 6.69 1 0.84 -0.17 0.805 2560 
CLCR CG -5070 0.48 1.06 0.85 -0.16 0.744 2541 
Legend table 3. Predictive performance of creatinine clearance (CLCR) as model covariate. 572 
CLCR 8h is creatinine clearance measured as urinary creatinine concentrations in an 8-hour 573 
urinary collection using an indwelling urinary catheter, CLCR MDRD is estimated glomerular 574 
filtration rate using the MDRD formula, CLCR CG is estimated glomerular filtration rate using 575 
the Cockroft-and-Gault formula. Based solely on the log likelihood values, none of the 576 
covariates improved the model fit. Nonetheless, the model with CLCR CG was used to predict 577 
piperacillin PK because it improved the observed versus predictive plots and it had the lowest 578 
AIC. 579 
  580 
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Capitation table 4. Fractional target attainment for varying renal functions 581 
CLCR CG Susceptible P. 
aeruginosa 
16g / 24h 
Susceptible P. 
aeruginosa 
24g / 24h 
30 0.999 1 
60 0.972 0.992 
90 0.909 0.962 
120 0.816 0.920 
150 0.748 0.855 
180 0.650 0.776 
210 0.556 0.738 
240 0.513 0.652 
270 0.450 0.571 
300 0.368 0.528 
Legend table 4. The FTA for a standard dose CI regimen (4g piperacillin loading dose 582 
followed by 16g/24h CI) and a high-dose CI regimen (4g piperacillin loading dose followed 583 
by 24g/24h CI) and a PK/PD target of 100% fT>4 X MIC for susceptible P. aeruginosa isolates 584 
(MIC ≤ 16 mg/L) and varying renal clearance (CLCR, estimated by the CG formula). Shaded 585 
areas represent scenarios where target exposure would be achieved in at least 95% of the 586 
isolates.  587 
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